Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Matthias StelljesThomas Büchner

Abstract

The majority of patients with acute myeloid leukemia (AML) who achieve complete remission (CR) relapse with conventional postremission chemotherapy. Allogeneic stem-cell transplantation (alloSCT) might improve survival at the expense of increased toxicity. It remains unknown for which patients alloSCT is preferable. We compared the outcome of 185 matched pairs of a large multicenter clinical trial (AMLCG99). Patients younger than 60 years who underwent alloSCT in first remission (CR1) were matched to patients who received conventional postremission therapy. The main matching criteria were AML type, cytogenetic risk group, patient age, and time in first CR. In the overall pairwise compared AML population, the projected 7-year overall survival (OS) rate was 58% for the alloSCT and 46% for the conventional postremission treatment group (P = .037; log-rank test). Relapse-free survival (RFS) was 52% in the alloSCT group compared with 33% in the control group (P < .001). OS was significantly better for alloSCT in patient subgroups with nonfavorable chromosomal aberrations, patients older than 45 years, and patients with secondary AML or high-risk myelodysplastic syndrome. For the entire patient cohort, postremission therapy was an in...Continue Reading

References

May 3, 2008·The New England Journal of Medicine·Richard F SchlenkUNKNOWN German-Austrian Acute Myeloid Leukemia Study Group
Aug 9, 2008·The New England Journal of Medicine·Thomas BüchnerJoachim Kienast
Dec 3, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas BüchnerWolfgang Hiddemann
Sep 25, 2009·The New England Journal of Medicine·Hugo F FernandezMartin S Tallman
Dec 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Annika DufourKarsten Spiekermann
Nov 26, 2010·The New England Journal of Medicine·Ted A GooleyGeorge B McDonald
Dec 20, 2011·American Journal of Hematology·Elihu H Estey
Sep 12, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas BüchnerMarkus Pfirrmann
Feb 27, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles A Schiffer
Feb 27, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard M Stone
Feb 27, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan K BurnettNigel Russell

❮ Previous
Next ❯

Citations

May 6, 2014·Current Treatment Options in Oncology·Peter H Wiernik
Sep 5, 2014·Cancer Immunology, Immunotherapy : CII·Marion SubkleweIris Bigalke
Dec 3, 2014·Hematology/oncology Clinics of North America·Tsila Zuckerman, Jacob M Rowe
Dec 2, 2015·Nature Reviews. Clinical Oncology·Catherine C CoombsRoss L Levine
Dec 3, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Erica D WarlickGerard Socie
Mar 24, 2016·Seminars in Hematology·Katharina Fleischhauer, Dietrich W Beelen
Jun 11, 2015·American Journal of Hematology·Daniela DamianiRenato Fanin
Nov 23, 2015·Best Practice & Research. Clinical Haematology·Richard M Stone
Jun 27, 2015·Seminars in Hematology·Felix S LichteneggerMarion Subklewe
Jun 27, 2015·Seminars in Hematology·Eolia Brissot, Mohamad Mohty
Jun 27, 2015·Journal of Clinical Medicine·Prithviraj Bose, Steven Grant
Jul 2, 2016·Blood Cancer Journal·I De Kouchkovsky, M Abdul-Hay
Dec 31, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edwin P Alyea
Aug 26, 2014·Future Oncology·Matthew D Galsky
Jan 17, 2015·Current Opinion in Hematology·Ofir Wolach, Richard M Stone
Aug 21, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Linus AngenendtChristoph Schliemann
Jul 27, 2017·Journal of Hematology & Oncology·Felix S LichteneggerMarion Subklewe
Sep 22, 2018·Cancers·Beatrice U MuellerThomas Pabst
May 10, 2016·Nature Reviews. Disease Primers·Asim KhwajaDavid C Linch
Sep 24, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Bhagirathbhai DholariaArnon Nagler
Apr 30, 2015·Deutsches Ärzteblatt International·Lutz P Müller, Carsten Müller-Tidow
Jan 19, 2020·Clinical Lymphoma, Myeloma & Leukemia·Prajwal DhakalVijaya Raj Bhatt
Jul 31, 2021·Journal for Immunotherapy of Cancer·Shelley HerbrichMarina Konopleva

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

© 2021 Meta ULC. All rights reserved